摘要
目的:为蒙药安神补心六味丸(吉如和-6)的进一步临床推广应用和研究开发提供参考。方法:采用德尔菲法,查阅相关文献资料,经过小组讨论、半结构式访谈等形式初步确定了安神补心六味组方配伍与临床应用特点的专家共识相关问卷层次和条目池,采用线上函询和现场发放调查问卷2种方式向从事蒙医药临床、科研、教学及生产的专家进行咨询,对目前安神补心六味丸的组方配伍、临床应用特点等进行评价,直至基本达成一致,最终确定安神补心六味丸的组方配伍和临床应用专家共识条目。结果:2轮函询共有42位专家参与。根据文献调研、小组讨论及半结构式访谈,第1轮设置函询指标16个;之后根据专家意见修改指标体系,第2轮设置函询指标17个。经过两轮函询,最终在安神补心六味丸的组方配伍和临床应用2方面17个条目达成共识,涵盖了本方的组方配伍、用量、主治病和合病证、用药时辰等主要内容。结论:通过共识发现将野牦牛心替换为牛心的安神补心六味丸依然有良好疗效,临床使用风险较低。
Objective:To provide a reference for the further clinical promotion,application,and research development of Mongolian medicine Anshen Buxin Liuwei Pills(Jiruhe-6).Methods:The Delphi method was employed,involving a review of relevant literature,group discussions,and semi-structured interviews to initially determine the hierarchical structure and entry pool of the expert consensus questionnaire regarding the formula composition and clinical application characteristics of Anshen Buxin Liuwei Pills.Online and on-site surveys were distributed to experts engaged in the clinical practice,research,teaching,and production of Mongolian medicine.The consultation aimed to evaluate the current formula composition and clinical application characteristics of Anshen Buxin Liuwei Pills until consensus was reached,resulting in the final formulation of the expert consensus on its composition and clinical application.Results:A total of 42 experts participated in the two rounds of consultation.Based on literature review,group discussions,and semi-structured interviews,the first round of consultation involved 16 inquiry indicators.After revising the indicator system based on expert feedback,the second round included 17 inquiry indicators.Through two rounds of consultation,consensus was reached on 17 entries concerning the formula composition and clinical application of Anshen Buxin Liuwei Pills,covering aspects such as its composition,dosage,primary and comorbid conditions,and optimal medication times.Conclusion:The consensus revealed that replacing wild yak heart with cow heart in Anshen Buxin Liuwei Pills still resulted in good therapeutic efficacy with low clinical risk.
作者
李青峰
李晓轩
胡汉琼
陈瑾
乌云斯日古楞
佟玉清
佟蛟龙
黄先菊
佟海英
LI Qingfeng;LI Xiaoxuan;HU Hanqiong;CHEN Jin;WUYUNSI Riguleng;TONG Yuqing;TONG Jiaolong;HUANG Xianju;TONG Haiying(School of Traditional Chinese Medicine,Beijing University of Chinese Medicine,Beijing 102488,China;Institute of Ethnic Medicines,Beijing University of Chinese Medicine,Beijing 102488,China;Department of Psychosomatic Medicine,Inner Mongolian International Mongolian Hospital,Hohhot 010065,China;Department of Cardiovascular Medicine,Affiliated Hospital of Inner Mongolia Minzu University,Tongliao 028000,China;Medical Department,Mongolian Hospital of Hinggan League,Ulanhot 137400,China;School of Pharmaceutical Sciences,South-central Minzu University,Wuhan 430074,China)
出处
《世界中医药》
CAS
北大核心
2024年第17期2647-2652,2662,共7页
World Chinese Medicine
基金
国家重点研发计划项目(2018YFC1708200,2018YFC1708206)
内蒙古自治区科技重大专项(2019ZD004)。
关键词
德尔菲法
蒙药
安神补心六味丸
配伍
临床应用
专家共识
Delphi method
Mongolian medicine
Anshen Buxin Liuwei Pills
Compatibility
Clinical application
Expert consensus